WO2003046130A2 - Methods for the identification of inhibitors of alpha-aminoadipate reductase and homocitrate synthase as antibiotics - Google Patents
Methods for the identification of inhibitors of alpha-aminoadipate reductase and homocitrate synthase as antibiotics Download PDFInfo
- Publication number
- WO2003046130A2 WO2003046130A2 PCT/US2002/036508 US0236508W WO03046130A2 WO 2003046130 A2 WO2003046130 A2 WO 2003046130A2 US 0236508 W US0236508 W US 0236508W WO 03046130 A2 WO03046130 A2 WO 03046130A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- test compound
- candidate
- antibiotic
- fungal
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 165
- 108010016900 L-aminoadipate-semialdehyde dehydrogenase Proteins 0.000 title claims abstract description 130
- 102000030882 L-Aminoadipate-Semialdehyde Dehydrogenase Human genes 0.000 title claims abstract description 127
- 108010082612 homocitrate synthase Proteins 0.000 title claims abstract description 127
- 239000003242 anti bacterial agent Substances 0.000 title claims abstract description 90
- 229940088710 antibiotic agent Drugs 0.000 title abstract description 11
- 239000003112 inhibitor Substances 0.000 title description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 260
- 241000233866 Fungi Species 0.000 claims abstract description 80
- 230000000694 effects Effects 0.000 claims abstract description 58
- 230000014509 gene expression Effects 0.000 claims abstract description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 179
- 238000012360 testing method Methods 0.000 claims description 178
- 230000002538 fungal effect Effects 0.000 claims description 159
- 230000012010 growth Effects 0.000 claims description 132
- 229920001184 polypeptide Polymers 0.000 claims description 115
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 115
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 115
- 230000003115 biocidal effect Effects 0.000 claims description 100
- 239000004472 Lysine Substances 0.000 claims description 57
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 claims description 46
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims description 46
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 42
- 150000001413 amino acids Chemical class 0.000 claims description 35
- 230000008859 change Effects 0.000 claims description 35
- 230000007918 pathogenicity Effects 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 230000000843 anti-fungal effect Effects 0.000 claims description 29
- 241001344133 Magnaporthe Species 0.000 claims description 28
- 230000015572 biosynthetic process Effects 0.000 claims description 27
- OYIFNHCXNCRBQI-BYPYZUCNSA-N L-2-aminoadipic acid Chemical compound OC(=O)[C@@H](N)CCCC(O)=O OYIFNHCXNCRBQI-BYPYZUCNSA-N 0.000 claims description 25
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 23
- UDRDAMWXUPMNJW-UHFFFAOYSA-N 4-bromo-2-methylaniline;hydrochloride Chemical compound Cl.CC1=CC(Br)=CC=C1N UDRDAMWXUPMNJW-UHFFFAOYSA-N 0.000 claims description 23
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 23
- 235000011180 diphosphates Nutrition 0.000 claims description 23
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 23
- 230000037361 pathway Effects 0.000 claims description 23
- 239000000126 substance Substances 0.000 claims description 23
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 22
- 230000027455 binding Effects 0.000 claims description 22
- 239000002609 medium Substances 0.000 claims description 22
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims description 20
- 230000007423 decrease Effects 0.000 claims description 19
- 108091033319 polynucleotide Proteins 0.000 claims description 19
- 102000040430 polynucleotide Human genes 0.000 claims description 19
- 239000002157 polynucleotide Substances 0.000 claims description 19
- 230000035899 viability Effects 0.000 claims description 18
- 239000001963 growth medium Substances 0.000 claims description 17
- 230000002068 genetic effect Effects 0.000 claims description 11
- -1 CoA Chemical compound 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 108020004999 messenger RNA Proteins 0.000 claims description 7
- 229940121375 antifungal agent Drugs 0.000 abstract description 22
- 208000015181 infectious disease Diseases 0.000 abstract description 17
- 238000006243 chemical reaction Methods 0.000 abstract description 15
- 230000005764 inhibitory process Effects 0.000 abstract description 15
- 230000003902 lesion Effects 0.000 abstract description 5
- 230000008958 fungal pathogenicity Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 96
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 52
- 241001344131 Magnaporthe grisea Species 0.000 description 50
- 239000000047 product Substances 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 24
- 102000004190 Enzymes Human genes 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 22
- 235000018977 lysine Nutrition 0.000 description 22
- 108020004414 DNA Proteins 0.000 description 21
- 208000016542 Progressive myoclonic epilepsy with dystonia Diseases 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 238000012216 screening Methods 0.000 description 20
- 238000003556 assay Methods 0.000 description 19
- 238000003780 insertion Methods 0.000 description 19
- 230000037431 insertion Effects 0.000 description 19
- 241000196324 Embryophyta Species 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 230000006870 function Effects 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 235000019766 L-Lysine Nutrition 0.000 description 15
- 229920001817 Agar Polymers 0.000 description 14
- 239000008272 agar Substances 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 239000012634 fragment Substances 0.000 description 12
- 230000008238 biochemical pathway Effects 0.000 description 11
- 239000000417 fungicide Substances 0.000 description 11
- 239000006151 minimal media Substances 0.000 description 11
- 238000000424 optical density measurement Methods 0.000 description 11
- 239000003446 ligand Substances 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000000423 cell based assay Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000010369 molecular cloning Methods 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 229920000742 Cotton Polymers 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 241001225321 Aspergillus fumigatus Species 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108090000854 Oxidoreductases Proteins 0.000 description 7
- 229940091771 aspergillus fumigatus Drugs 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 235000020061 kirsch Nutrition 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 240000007594 Oryza sativa Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- 102000004316 Oxidoreductases Human genes 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000034373 developmental growth involved in morphogenesis Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000009036 growth inhibition Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 238000012809 post-inoculation Methods 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 230000001174 ascending effect Effects 0.000 description 5
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 230000000855 fungicidal effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 210000001938 protoplast Anatomy 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000011573 trace mineral Substances 0.000 description 5
- 235000013619 trace mineral Nutrition 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 238000012795 verification Methods 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 206010039509 Scab Diseases 0.000 description 4
- 244000061456 Solanum tuberosum Species 0.000 description 4
- 235000002595 Solanum tuberosum Nutrition 0.000 description 4
- 244000301083 Ustilago maydis Species 0.000 description 4
- 235000015919 Ustilago maydis Nutrition 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000007824 enzymatic assay Methods 0.000 description 4
- 244000053095 fungal pathogen Species 0.000 description 4
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 4
- 229940097277 hygromycin b Drugs 0.000 description 4
- 230000009610 hypersensitivity Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000001823 molecular biology technique Methods 0.000 description 4
- 239000006877 oatmeal agar Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- 230000017105 transposition Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- XKJVEVRQMLKSMO-SSDOTTSWSA-N (2R)-homocitric acid Chemical compound OC(=O)CC[C@](O)(C(O)=O)CC(O)=O XKJVEVRQMLKSMO-SSDOTTSWSA-N 0.000 description 3
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000235349 Ascomycota Species 0.000 description 3
- 241000351920 Aspergillus nidulans Species 0.000 description 3
- 241000221198 Basidiomycota Species 0.000 description 3
- 241000233652 Chytridiomycota Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108700005088 Fungal Genes Proteins 0.000 description 3
- 241000223218 Fusarium Species 0.000 description 3
- 239000006142 Luria-Bertani Agar Substances 0.000 description 3
- 208000031888 Mycoses Diseases 0.000 description 3
- 241000228150 Penicillium chrysogenum Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 101100370749 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) trpC1 gene Proteins 0.000 description 3
- 241000758405 Zoopagomycotina Species 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000005516 coenzyme A Substances 0.000 description 3
- 229940093530 coenzyme a Drugs 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000002060 fluorescence correlation spectroscopy Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910052759 nickel Inorganic materials 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 101150016309 trpC gene Proteins 0.000 description 3
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 2
- 241000216654 Armillaria Species 0.000 description 2
- 241000216633 Armillaria gallica Species 0.000 description 2
- 241001659842 Armillaria luteobubalina Species 0.000 description 2
- 244000221226 Armillaria mellea Species 0.000 description 2
- 241000216635 Armillaria ostoyae Species 0.000 description 2
- 108091005658 Basic proteases Proteins 0.000 description 2
- 241000228438 Bipolaris maydis Species 0.000 description 2
- 241001262168 Bipolaris stenospila Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 241000947067 Cercospora zeae-maydis Species 0.000 description 2
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 2
- 241000228437 Cochliobolus Species 0.000 description 2
- 241000222233 Colletotrichum musae Species 0.000 description 2
- 241001123530 Cronartium Species 0.000 description 2
- 241000223211 Curvularia lunata Species 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241001480035 Epidermophyton Species 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 101001091269 Escherichia coli Hygromycin-B 4-O-kinase Proteins 0.000 description 2
- 235000017261 Fritillaria camtschatcensis Nutrition 0.000 description 2
- 241000223194 Fusarium culmorum Species 0.000 description 2
- 241000223195 Fusarium graminearum Species 0.000 description 2
- 241000223221 Fusarium oxysporum Species 0.000 description 2
- 241001149475 Gaeumannomyces graminis Species 0.000 description 2
- 241001480617 Ganoderma adspersum Species 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 241000223247 Gloeocercospora Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000735439 Heterobasidion annosum Species 0.000 description 2
- 101150090950 Hsc70-1 gene Proteins 0.000 description 2
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- 241001480037 Microsporum Species 0.000 description 2
- 241001518836 Monilinia fructigena Species 0.000 description 2
- 240000008790 Musa x paradisiaca Species 0.000 description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 2
- 229910004619 Na2MoO4 Inorganic materials 0.000 description 2
- 241000221671 Ophiostoma ulmi Species 0.000 description 2
- 235000005044 Oryza sativa Indica Group Nutrition 0.000 description 2
- 241000293001 Oxytropis besseyi Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241000845082 Panama Species 0.000 description 2
- 235000002245 Penicillium camembertii Nutrition 0.000 description 2
- 241001123663 Penicillium expansum Species 0.000 description 2
- 241000395955 Periconia Species 0.000 description 2
- 241000233622 Phytophthora infestans Species 0.000 description 2
- 241000123196 Piptoporus betulinus Species 0.000 description 2
- 241001503436 Plasmodiophora brassicae Species 0.000 description 2
- 101100505672 Podospora anserina grisea gene Proteins 0.000 description 2
- 241000222642 Polyporus squamosus Species 0.000 description 2
- 241000221301 Puccinia graminis Species 0.000 description 2
- 241000231139 Pyricularia Species 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 241000813090 Rhizoctonia solani Species 0.000 description 2
- 101100150366 Schizosaccharomyces pombe (strain 972 / ATCC 24843) sks2 gene Proteins 0.000 description 2
- 241000221696 Sclerotinia sclerotiorum Species 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- 241001219481 Spongospora subterranea Species 0.000 description 2
- 101001091268 Streptomyces hygroscopicus Hygromycin-B 7''-O-kinase Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000589500 Thermus aquaticus Species 0.000 description 2
- 235000009430 Thespesia populnea Nutrition 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 102000008579 Transposases Human genes 0.000 description 2
- 108010020764 Transposases Proteins 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 241001286670 Ulmus x hollandica Species 0.000 description 2
- 241000221577 Uromyces appendiculatus Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 240000000300 Zizania aquatica Species 0.000 description 2
- 235000002636 Zizania aquatica Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000010801 foot rot Diseases 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 101150093275 hcs1 gene Proteins 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 244000000003 plant pathogen Species 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011684 sodium molybdate Substances 0.000 description 2
- TVXXNOYZHKPKGW-UHFFFAOYSA-N sodium molybdate (anhydrous) Chemical compound [Na+].[Na+].[O-][Mo]([O-])(=O)=O TVXXNOYZHKPKGW-UHFFFAOYSA-N 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 108030003618 3,4-dihydroxy-2-butanone-4-phosphate synthases Proteins 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 101000854353 Agrocybe aegerita Ribonuclease ageritin Proteins 0.000 description 1
- 241000919511 Albugo Species 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 241000429837 Alternaria caespitosa Species 0.000 description 1
- 241001110471 Anisogramma Species 0.000 description 1
- 241001335261 Anthracoidea Species 0.000 description 1
- 241000123370 Antrodia Species 0.000 description 1
- 241001444083 Aphanomyces Species 0.000 description 1
- 241001344109 Apiognomonia Species 0.000 description 1
- 241001425480 Apiosporina Species 0.000 description 1
- 101100110006 Arabidopsis thaliana ASD1 gene Proteins 0.000 description 1
- 241000222195 Ascochyta Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 101000669426 Aspergillus restrictus Ribonuclease mitogillin Proteins 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710130006 Beta-glucanase Proteins 0.000 description 1
- 241001465178 Bipolaris Species 0.000 description 1
- 241000228439 Bipolaris zeicola Species 0.000 description 1
- 241000222490 Bjerkandera Species 0.000 description 1
- 241000335423 Blastomyces Species 0.000 description 1
- 241000190146 Botryosphaeria Species 0.000 description 1
- 241001465180 Botrytis Species 0.000 description 1
- 241000123650 Botrytis cinerea Species 0.000 description 1
- 241000233684 Bremia Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000221544 Ceratobasidium Species 0.000 description 1
- 241000221866 Ceratocystis Species 0.000 description 1
- 241001157813 Cercospora Species 0.000 description 1
- 241001065113 Cercosporidium Species 0.000 description 1
- 241001318789 Cerotelium Species 0.000 description 1
- 241000293772 Cerrena Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 102000005469 Chitin Synthase Human genes 0.000 description 1
- 108700040089 Chitin synthases Proteins 0.000 description 1
- 241000593872 Chondrostereum Species 0.000 description 1
- 241000865175 Chrysomyxa Species 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- 241000221760 Claviceps Species 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 241000222380 Coleosporium Species 0.000 description 1
- 241000222199 Colletotrichum Species 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 241001529717 Corticium <basidiomycota> Species 0.000 description 1
- 241000609458 Corynespora Species 0.000 description 1
- 241000221755 Cryphonectria Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241001231282 Cryptosphaeria Species 0.000 description 1
- 229910016508 CuCl22H2O Inorganic materials 0.000 description 1
- 241000371644 Curvularia ravenelii Species 0.000 description 1
- 241000959617 Cyathus Species 0.000 description 1
- 241000272277 Cymadothea Species 0.000 description 1
- 241000235819 Cytospora Species 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 241000123294 Daedaleopsis Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241001508802 Diaporthe Species 0.000 description 1
- 241000555695 Didymella Species 0.000 description 1
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 1
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 1
- 241000461780 Diplocarpon Species 0.000 description 1
- 241000935926 Diplodia Species 0.000 description 1
- 241000985261 Discohainesia Species 0.000 description 1
- 241000560922 Discula Species 0.000 description 1
- 241000986492 Dothistroma Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000123301 Echinodontium Species 0.000 description 1
- 241000125117 Elsinoe Species 0.000 description 1
- 241001246273 Endothia Species 0.000 description 1
- 241000895612 Entyloma Species 0.000 description 1
- 241000221752 Epichloe Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 241000221787 Erysiphe Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000221997 Exobasidium Species 0.000 description 1
- 241000306559 Exserohilum Species 0.000 description 1
- 241000123326 Fomes Species 0.000 description 1
- 241001480537 Fomitopsis Species 0.000 description 1
- 241001149504 Gaeumannomyces Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 241000123332 Gloeophyllum Species 0.000 description 1
- 241001619421 Gloeoporus Species 0.000 description 1
- 241001620302 Glomerella <beetle> Species 0.000 description 1
- 241001625377 Gnomoniella Species 0.000 description 1
- 241000555709 Guignardia Species 0.000 description 1
- 241000221557 Gymnosporangium Species 0.000 description 1
- 241000190090 Herpotrichia Species 0.000 description 1
- 241000735452 Heterobasidion Species 0.000 description 1
- 101710091977 Hydrophobin Proteins 0.000 description 1
- 241000123247 Inonotus Species 0.000 description 1
- 241000222342 Irpex Species 0.000 description 1
- 241000222058 Kabatiella Species 0.000 description 1
- 241000907252 Kabatina Species 0.000 description 1
- 241000222689 Laetiporus Species 0.000 description 1
- 241000329436 Laetisaria Species 0.000 description 1
- 241000935930 Lasiodiplodia Species 0.000 description 1
- 241000959612 Laxitextum Species 0.000 description 1
- 241000382751 Leptographium Species 0.000 description 1
- 241000228456 Leptosphaeria Species 0.000 description 1
- 241000555723 Leptosphaerulina Species 0.000 description 1
- 241001344101 Linospora Species 0.000 description 1
- 241001420853 Lophodermella Species 0.000 description 1
- 241000907272 Lophodermium Species 0.000 description 1
- 241001625930 Luria Species 0.000 description 1
- 241001495424 Macrophomina Species 0.000 description 1
- 241001344132 Magnaporthiopsis poae Species 0.000 description 1
- 241000379993 Magnaporthiopsis rhizophila Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001661269 Marssonina Species 0.000 description 1
- 241000221573 Melampsora Species 0.000 description 1
- 241001409806 Melampsorella Species 0.000 description 1
- 241000934179 Meria <ascomycete> Species 0.000 description 1
- 241001314407 Microsphaera Species 0.000 description 1
- 241001518729 Monilinia Species 0.000 description 1
- 241001643490 Monochaetia Species 0.000 description 1
- 241000221638 Morchella Species 0.000 description 1
- 241000131448 Mycosphaerella Species 0.000 description 1
- 241000223251 Myrothecium Species 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 241000379990 Nakataea oryzae Species 0.000 description 1
- 241001226034 Nectria <echinoderm> Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 241000189150 Nigrospora Species 0.000 description 1
- 241000233654 Oomycetes Species 0.000 description 1
- 241001465312 Ophiosphaerella Species 0.000 description 1
- 241000221871 Ophiostoma Species 0.000 description 1
- 108010055012 Orotidine-5'-phosphate decarboxylase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241001619479 Perenniporia Species 0.000 description 1
- 241001123526 Peridermium Species 0.000 description 1
- 241001223281 Peronospora Species 0.000 description 1
- 241000893212 Pestalotia Species 0.000 description 1
- 241000907277 Phaeocryptopus Species 0.000 description 1
- 241000123127 Phaeolus Species 0.000 description 1
- 241000440444 Phakopsora Species 0.000 description 1
- 241000123107 Phellinus Species 0.000 description 1
- 241000222831 Phialophora <Chaetothyriales> Species 0.000 description 1
- 241001503951 Phoma Species 0.000 description 1
- 241001480007 Phomopsis Species 0.000 description 1
- 241001409766 Phragmidium Species 0.000 description 1
- 241000534544 Phyllachora Species 0.000 description 1
- 241000579813 Phyllactinia Species 0.000 description 1
- 241000519856 Phyllosticta Species 0.000 description 1
- 241000084447 Phymatotrichopsis Species 0.000 description 1
- 241000233614 Phytophthora Species 0.000 description 1
- 241001503464 Plasmodiophora Species 0.000 description 1
- 241000233626 Plasmopara Species 0.000 description 1
- 241001136503 Pleospora Species 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 241000896242 Podosphaera Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241001281802 Pseudoperonospora Species 0.000 description 1
- 241001480433 Pseudopeziza Species 0.000 description 1
- 241000787858 Pseudoseptoria Species 0.000 description 1
- 241000221300 Puccinia Species 0.000 description 1
- 241000221535 Pucciniales Species 0.000 description 1
- 241000865185 Pucciniastrum Species 0.000 description 1
- 241000228453 Pyrenophora Species 0.000 description 1
- 238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000934240 Rhabdocline Species 0.000 description 1
- 241001361634 Rhizoctonia Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000579690 Rhizosphaera <ascomycete fungus> Species 0.000 description 1
- 241001515786 Rhynchosporium Species 0.000 description 1
- 241000214626 Rhytisma <ascomycete> Species 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000222480 Schizophyllum Species 0.000 description 1
- 241001311582 Schizopora Species 0.000 description 1
- 241000879372 Scirrhia Species 0.000 description 1
- 241001183193 Sclerophthora Species 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 241000221662 Sclerotinia Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 241000959592 Scytinostroma Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241001533598 Septoria Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241001648762 Sirococcus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 241000935922 Sphaeropsis Species 0.000 description 1
- 241000579741 Sphaerotheca <fungi> Species 0.000 description 1
- 241000893100 Sporisorium Species 0.000 description 1
- 241000533281 Stagonospora Species 0.000 description 1
- 241000371621 Stemphylium Species 0.000 description 1
- 241000692760 Stenocarpella Species 0.000 description 1
- 241000222646 Stereum Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000228446 Taphrina Species 0.000 description 1
- 241000865903 Thielaviopsis Species 0.000 description 1
- 241000722133 Tilletia Species 0.000 description 1
- 241000222354 Trametes Species 0.000 description 1
- 241001409775 Tranzschelia Species 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000591119 Trichophyton sp. Species 0.000 description 1
- 241000694565 Tubakia Species 0.000 description 1
- 241000959260 Typhula Species 0.000 description 1
- 241000510929 Uncinula Species 0.000 description 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
- 241001154828 Urocystis <tapeworm> Species 0.000 description 1
- 241000221576 Uromyces Species 0.000 description 1
- 241000221566 Ustilago Species 0.000 description 1
- 241001645362 Valsa Species 0.000 description 1
- 241000317942 Venturia <ichneumonid wasp> Species 0.000 description 1
- 241000082085 Verticillium <Phyllachorales> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241001523965 Xylaria Species 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001775 anti-pathogenic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000002599 biostatic effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000012677 causal agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 210000000167 fungal chromosome Anatomy 0.000 description 1
- 244000000004 fungal plant pathogen Species 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 108010002685 hygromycin-B kinase Proteins 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000012750 in vivo screening Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000004215 spore Anatomy 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical class CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
- C12Y102/01031—L-Aminoadipate-semialdehyde dehydrogenase (1.2.1.31), i.e. alpha-aminoadipate reductase
Definitions
- the invention relates generally to methods for the identification of antibiotics, preferably antifungals that affect the biosynthesis of lysine.
- Filamentous fungi are the causal agents responsible for many serious pathogenic infections of plants and animals. Since fungi are eukaryotes, and thus more similar to their host organisms than, for example bacteria, the treatment of infections by fungi poses special risks and challenges not encountered with other types of infections.
- One such fungus is Magnaporthe grisea, the fungus that causes rice blast disease. It is an organism that poses a significant threat to food supplies worldwide.
- plant pathogens of economic importance mclude the pathogens in the genera Agaricus, Alternaria, Anisogramma, Anthracoidea, Antrodia, Apiognomonia, Apiosporina, Annillaria, Ascochyta, Aspergillus, Bipolaris, Bjerkandera, Botryosphaeria, Botrytis, Ceratobasidium, Ceratocystis, Cercospora, Cercosporidium, Cerotelium, Cerrena, Chondrostereum, Chryphonectria, Chrysomyxa, Cladosporium, Claviceps, Cochliobolus, Coleosporium, Colletotrichium, Colletotrichum, Corticium, Corynespora, Cronartium, Cryphonectria, Cryptosphaeria, Cyathus, Cymadothea, Cytospora, Daedaleopsis, Diaporthe, Didymella, Diplocarpon, Dip
- fungal diseases in animals are caused by fungi in the genera, Fusarium, Blastomyces, Microsporum, Trichophyton, Epidermophyton, Candida, Histoplamsa, Pneumocystis, Cryptococcus, other Aspergilli, and others.
- the control of fungal diseases in plants and animals is usually mediated by chemicals that inhibit the growth, proliferation, and/or pathogenicity of the fungal organisms.
- a pathogenic organism has been defined as an organism that causes, or is capable of causing disease. Pathogenic organisms propagate on or in tissues and may obtain nutrients and other essential materials from their hosts. A substantial amount of work concerning filamentous fungal pathogens has been performed with the human pathogen, Aspergillus fumigatus. Shibuya et al. (Shibuya, K., M. Takaoka, et al.
- Microb Pathog 27: 123 - 31 have shown that the deletion of either of two suspected pathogenicity related genes encoding an alkaline protease or a hydrophobin (rodlet) respectively, did not reduce mortality of mice infected with these mutant strains.
- Smith et al. Smith, J. M., C. M. Tang, et al. (1994) Infect Immun 62: 5247 - 54 (PMID: 7960101)
- Reichard et al. Reichard, U., M.
- the present inventors have discovered that in vivo disruption of the gene encoding ⁇ -Aminoadipate Reductase and, separately, in vivo disruption of the gene encoding Homocitrate Synthase in M ⁇ gn ⁇ porthe grisea each prevents or inhibits the pathogenicity of the fungus. Both of these enzymes are involved in the biosynthesis of lysine.
- ⁇ - Aminoadipate Reductase and Homocitrate Synthase are each essential for normal rice blast pathogenicity, and can be used as a target for the identification of antibiotics, preferably fungicides.
- the present invention provides methods for the identification of compounds that inhibit the expression or activity of ⁇ -Aminoadipate Reductase or, separately, of Homocitrate Synthase.
- the methods of the invention are useful for the identification of antibiotics, preferably fungicides.
- Figure 1 shows the reaction performed by ⁇ - Ammoadipate Reductase (AARl) reaction.
- the Substrates/Products are L-2-Aminoadipate + NADPH + ATP and the Products/Substrates are L-2-Aminoadipate 6-semialdehyde + NADP+ + AMP + pyrophosphate + H 2 O.
- the function of the ⁇ -Aminoadipate Reductase enzyme is the interconversion of L-2-Aminoadipate, NADPH, and ATP to L-2 -Aminoadipate 6- semialdehyde. NADP+, AMP, pyrophosphate, and H O. This reaction is part of the lysine biosynthesis pathway.
- Figure 2 shows a digital image showing the effect of AARl gene disruption on Magnaporthe grisea pathogenicity using whole plant infection assays.
- Rice variety CO39 was inoculated with wild-type and the transposon insertion strains, KOl-1 and KOl-11.
- Leaf segments were imaged at five days post-inoculation.
- FIG. 3 Verification of Gene Function by Analysis of Nutritional Requirements. Wild-type and transposon insertion strains, KOl-1 and KOl-11, were grown in (A) minimal media and (B) minimal media with the addition of L-lysine, respectively.
- the x-axis shows time in days and the y-axis shows turbidity measured at 490 nanometers and 750 nanometers.
- the symbols represent wildtype (— ⁇ --), transposon strain KOl-1 (-- ⁇ —), and transposon strain KOI -11 (—A—).
- Figure 4 shows the reaction performed by the homocitrate synthase (HCS1) reaction.
- the Substrates/Products are Acetyl CoA + H 2 O + 2-oxoglutarate and the Products/Substrates are 2-hydroxybutane-l,2,4-tricarboxylate + CoA.
- the function of the homocitrate synthase enzyme is the interconversion of Acetyl CoA, 2- oxoglutarate, and H 2 O to 2-hydroxybutane-l,2,4-tricarboxylate and CoA. This reaction is part of the lysine biosynthesis pathway.
- Figure 5 shows a digital image showing the effect of HCS1 gene disruption on Magnaporthe grisea pathogenicity using whole plant infection assays.
- Rice variety CO39 was inoculated with wild-type and the transposon insertion strains, KOl-1 and KOI -2. Leaf segments were imaged at five days post-inoculation.
- Wild-type and transposon insertion strains were grown in (A) minimal media and (B) minimal media with the addition of L-lysine, respectively.
- the x-axis shows time in days and the y-axis shows turbidity measured at 490 nanometers and 750 nanometers.
- the symbols represent wildtype (-- ⁇ --), transposon strain
- KOl-1 (-- ⁇ —), and transposon strain KOI -2 (—A.—).
- active against in the context of compounds, agents, or compositions having antibiotic activity indicates that the compound exerts an effect on a particular target or targets which is deleterious to the in vitro and/or in vivo growth of an organism having that target or targets.
- a compound active against a gene exerts an action on a target which affects an expression product of that gene. This does not necessarily mean that the compound acts directly on the expression product of the gene, but instead indicates that the compound affects the expression product in a deleterious manner.
- the direct target of the compound may be, for example, at an upstream component which reduces transcription from the gene, resulting in a lower level of expression.
- the compound may affect the level of translation of a polypeptide expression product, or may act on a downstream component of a biochemical pathway in which the expression product of the gene has a major biological role. Consequently, such a compound can be said to be active against the gene, against the gene product, or against the related component either upstream or downstream of that gene or expression product. While the term “active against” encompasses a broad range of potential activities, it also implies some degree of specificity of target. Therefore, for example, a general protease is not “active against” a particular gene which produces a polypeptide product. In contrast, a compound which inhibits a particular enzyme is active against that enzyme and against the gene which codes for that enzyme.
- allele refers to any of the alternative forms of a gene that may occur at a given locus.
- ⁇ -Aminoadipate Reductase EC 1.2.1.31
- ⁇ -Aminoadipate Reductase EC 1.2.1.31
- Aminoadipate Reductase polypeptide, ⁇ -Aminoadipate semialdehyde dehydrogenase, or Alpha-Aminoadipate Reductase is synonymous with "the AARl gene product” or the “the ASD1 gene product” and refers to an enzyme that catalyses the interconversion of L-2-Aminoadipate, NADPH, and ATP with L-2-Aminoadipate 6- semialdehyde, NADP+, AMP, pyrophosphate, and H 2 O.
- antibiotic refers to any substance or compound that when contacted with a living cell, organism, virus, or other entity capable of replication, results in a reduction of growth, viability, or pathogenicity of that entity.
- binding refers to a non-covalent or a covalent interaction, preferably non-covalent, that holds two molecules together.
- two such molecules could be an enzyme and an inhibitor of that enzyme.
- Non-covalent interactions include hydrogen bonding, ionic interactions among charged groups, van der Waals interactions and hydrophobic interactions among nonpolar groups. One or more of these interactions can mediate the binding of two molecules to each other.
- biochemical pathway refers to a connected series of biochemical reactions normally occurring in a cell, or more broadly a cellular event such as cellular division or DNA replication.
- steps in such a biochemical pathway act in a coordinated fashion to produce a specific product or products or to produce some other particular biochemical action.
- Such a biochemical pathway requires the expression product of a gene if the absence of that expression product either directly or indirectly prevents the completion of one or more steps in that pathway, thereby preventing or significantly reducing the production of one or more normal products or effects of that pathway.
- an agent specifically inhibits such a biochemical pathway requiring the expression product of a particular gene if the presence of the agent stops or substantially reduces the completion of the series of steps in that pathway.
- Such an agent may, but does not necessarily, act directly on the expression product of that particular gene.
- cDNA means complementary deoxyribonucleic acid.
- CoA means coenzyme A.
- condition lethal refers to a mutation permitting growth and/or survival only under special growth or environmental conditions.
- the term "cosmid” refers to a hybrid vector, used in gene cloning, that includes a cos site (from the lambda bacteriophage). It also contains drug resistance marker genes and other plasmid genes. Cosmids are especially suitable for cloning large genes or multigene fragments.
- the term "dominant allele” refers to a dominant mutant allele in which a discernable mutant phenotype can be detected when this mutation is present in an organism that also contains a wild type (non-mutant), recessive allele, or other dominant allele.
- DNA means deoxyribonucleic acid.
- ELISA means enzyme-linked immunosorbent assay.
- Fungi refers to whole fungi, fungal organs and tissues (e.g., asci, hyphae, pseudohyphae, rhizoid, sclerotia, sterigmata, spores, sporodochia, sporangia, synnemata, conidia, ascostroma, cleistothecia, mycelia, perithecia, basidia and the like), spores, fungal cells and the progeny thereof.
- Fungi are a group of organisms (about 50,000 known species), including, but not limited to, mushrooms, mildews, moulds, yeasts, etc., comprising the kingdom Fungi.
- Fungi can either exist as single cells or make up a multicellular body called a mycelium, which consists of filaments known as hyphae. Most fungal cells are multinucleate and have cell walls, composed chiefly of chitin. Fungi exist primarily in damp situations on land and, because of the absence of chlorophyll and thus the inability to manufacture their own food by photosynthesis, are either parasites on other organisms or saprotrophs feeding on dead organic matter. The principal criteria used in classification are the nature of the spores produced and the presence or absence of cross walls within the hyphae. Fungi are distributed worldwide in terrestrial, freshwater, and marine habitats. Some live in the soil. Many pathogenic fungi cause disease in animals, and man or in plants, while some saprotrophs are destructive to timber, textiles, and other materials. Some fungi form associations with other organisms, most notably with algae to form lichens.
- fungicide refers to an antibiotic substance or compound that kills or suppresses the growth, viability, or pathogenicity of at least one fungus, fungal cell, fungal tissue or spore.
- each gene is composed of a linear chain of deoxyribonucleotides which can be referred to by the sequence of nucleotides forming the chain.
- sequence is used to indicate both the ordered listing of the nucleotides which form the chain, and the chain, itself, which has that sequence of nucleotides.
- sequence is used in the similar way in referring to RNA chains, linear chains made of ribonucleotides.
- the gene may include regulatory and control sequences, sequences which can be transcribed into an RNA molecule, and may contain sequences with unknown function.
- RNA transcription products are messenger RNAs (mRNAs), which include sequences which are translated into polypeptides and may include sequences which are not translated. It should be recognized that small differences in nucleotide sequence for the same gene can exist between different fungal strains, or even within a particular fungal strain, without altering the identity of the gene.
- mRNAs messenger RNAs
- growth or “cell growth” of an organism refers to an increase in mass, density, or number of cells of said organism.
- Some common methods for the measurement of growth include the determination of the optical density of a cell suspension, the counting of the number of cells in a fixed volume, the counting of the number of cells by measurement of cell division, the measurement of cellular mass or cellular volume, and the like.
- growth conditional phenotype indicates that a fungal strain having such a phenotype exhibits a significantly greater difference in growth rates in response to a change in one or more of the culture parameters than an otherwise similar strain not having a growth conditional phenotype.
- a growth conditional phenotype is described with respect to a single growth culture parameter, such as temperature.
- a temperature (or heat-sensitive) mutant i.e., a fungal strain having a heat-sensitive phenotype
- such mutants preferably also show intermediate growth rates at intermediate, or semi-permissive, temperatures. Similar responses also result from the appropriate growth changes for other types of growth conditional phenotypes.
- H 2 O means water
- AARl means a gene encoding ⁇ -Aminoadipate Reductase activity, referring to an enzyme that catalyses the interconversion of L-2- Aminoadipate, NADPH, and ATP with L-2-Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H 2 O.
- heterologous AARl gene means a gene, not derived from Magnaporthe grisea, and having: at least 50% sequence identity, preferably 60%, 70%, 80%, 90%, 95%, 99% sequence identity and each integer unit of sequence identity from 50-100% in ascending order to SEQ ID NO: 1 or SEQ ID NO: 2; or at least 10% of the activity of a Magnaporthe grisea ⁇ -Aminoadipate Reductase , preferably 25%, 50%, 75%, 90%, 95%, 99% and each integer unit of activity from 10-100% in ascending order.
- HCS1 means a gene encoding homocitrate synthase activity, referring to an enzyme that catalyses the interconversion of acetyl-CoA, H 2 O, and 2-oxoglutarate with 2-hydroxybutane-l,2,4-tricarboxylate and CoA.
- heterologous HCS1 gene means a gene, not derived from Magnaporthe grisea, and having: at least 50% sequence identity, preferably 60%), 70%, 80%), 90%), 95%, 99% sequence identity and each integer unit of sequence identity from 50-100% in ascending order to SEQ ID NO: 1 or SEQ ID NO: 2; or at least 10%) of the activity of a Magnaporthe grisea homocitrate synthase, preferably 25%, 50%, 75%, 90%, 95%, 99% and each integer unit of activity from 10-100% in ascending order.
- homocitrate synthase EC 4.1.3.21
- homocitrate synthase polypeptide is synonymous with “the HCSl gene product” and refers to an enzyme that catalyses the interconversion of acetyl-CoA, H 2 O, and 2-oxoglutarate with 2-hydroxybutane-l,2,4-tricarboxylate and CoA.
- His-Tag refers to an encoded polypeptide consisting of multiple consecutive histidine amino acids.
- HPLC high pressure liquid chromatography
- hph hygromycin B phosphotransferase
- hygromycin resistance gene refer to the E. coli hygromycin phosphotransferase gene or gene product.
- hygromycin B refers to an aminoglycosidic antibiotic, used for selection and maintenance of eukaryotic cells containing the E. coli hygromycin resistance gene.
- Hypersensitive refers to a phenotype in which cells are more sensitive to antibiotic compounds than are wild-type cells of similar or identical genetic background.
- Hyposensitive refers to a phenotype in which cells are less sensitive to antibiotic compounds than are wild-type cells of similar or identical genetic background.
- imperfect state refers to a classification of a fungal organism having no demonstrable sexual life stage.
- inhibitor refers to a chemical substance that inactivates the enzymatic activity of ⁇ -Aminoadipate Reductase or Homocitrate Synthase, or substantially reduces the level of enzymatic activity, wherein “substantially” means a reduction at least as great as the standard deviation for a measurement, preferably a reduction by 50%>, more preferably a reduction of at least one magnitude, i.e. to 10%.
- the inhibitor may function by interacting directly with the enzyme, a cofactor of the enzyme, the substrate of the enzyme, or any combination thereof.
- a polynucleotide may be "introduced" into a fungal cell by any means known to those of skill in the art, including transfection, transformation or transduction, transposable element, electroporation, particle bombardment, infection and the like.
- the introduced polynucleotide may be maintained in the cell stably if it is incorporated into a non-chromosomal autonomous replicon or integrated into the fungal chromosome.
- the introduced polynucleotide may be present on an extra-chromosomal non-replicating vector and be transiently expressed or transiently active.
- the term “knockout” or “gene disruption” refers to the creation of organisms carrying a null mutation (a mutation in which there is no active gene product), a partial null mutation or mutations, or an alteration or alterations in gene regulation by interrupting a DNA sequence through insertion of a foreign piece of DNA. Usually the foreign DNA encodes a selectable marker.
- LB agar means Luria's Broth agar.
- method of screening means that the method is suitable, and is typically used, for testing for a particular property or effect in a large number of compounds. Typically, more than one compound is tested simultaneously (as in a 96-well microtiter plate), and preferably significant portions of the procedure can be automated, "method of screening” also refers to determining a set of different properties or effects of one compound simultaneously.
- mRNA messenger ribonucleic acid
- mutant form of a gene refers to a gene which has been altered, either naturally or artificially, changing the base sequence of the gene.
- the change in the base sequence may be of several different types, including changes of one or more bases for different bases, deletions, and/or insertions, such as by a transposon.
- a normal form of a gene wild type is a form commonly found in natural populations of an organism. Commonly a single form of a gene will predominate in natural populations.
- such a gene is suitable as a normal form of a gene, however, other forms which provide similar functional characteristics may also be used as a normal gene, h particular, a normal form of a gene does not confer a growth conditional phenotype on the strain having that gene, while a mutant form of a gene suitable for use in these methods does provide such a growth conditional phenotype.
- Ni refers to nickel.
- Ni-NTA refers to nickel sepharose.
- one form of a gene is synonymous with the term
- gene and a “different form” of a gene refers to a gene that has greater than 49% sequence identity and less than 100%> sequence identity with said first form.
- pathogenicity refers to a capability of causing disease.
- the term is applied to parasitic microorganisms in relation to their hosts.
- PCR means polymerase chain reaction.
- the "percent (%>) sequence identity" between two polynucleotide or two polypeptide sequences is determined according to the either the BLAST program (Basic Local Alignment Search Tool; (Altschul, S.F., W. Gish, et al. (1990) J Mol Biol 215: 403 - 10 (PMTD: 2231712)) at the National Center for Biotechnology or using Smith Waterman Alignment (Smith, T. F. and M. S. Waterman (1981) J Mol Biol 147: 195 - 7 (PMID: 7265238)) as incorporated into GeneMatcher PlusTM.
- BLAST program Basic Local Alignment Search Tool
- polypeptide is meant a chain of at least two amino acids joined by peptide bonds.
- the chain may be linear, branched, circular or combinations thereof.
- polypeptides are from about 10 to about 1000 amino acids in length, more preferably 10-50 amino acids in length.
- the polypeptides may contain amino acid analogs and other modifications, including, but not limited to glycosylated or phosphorylated residues.
- the term “proliferation” is synonymous to the term “growth”.
- the term “reverse transcriptase-PCR” means reverse transcription- polymerase chain reaction.
- RNA means ribonucleic acid.
- semi-permissive conditions are conditions in which the relevant culture parameter for a particular growth conditional phenotype is intermediate between permissive conditions and non-permissive conditions. Consequently, in semi-permissive conditions an organism having a growth conditional phenotype will exhibit growth rates intermediate between those shown in permissive conditions and non-permissive conditions. In general, such intermediate growth rate may be due to a mutant cellular component which is partially functional under semi-permissive conditions, essentially fully functional under permissive conditions, and is non-functional or has very low function under non-permissive conditions, where the level of function of that component is related to the growth rate of the organism. An intermediate growth rate may also be a result of a nutrient substance or substances that are present in amounts not sufficient for optimal growth rates to be achieved.
- Sensitivity phenotype refers to a phenotype that exhibits either hypersensitivity or hyposensitivity.
- binding refers to an interaction between ⁇ -Aminoadipate Reductase and a molecule or compound, wherein the interaction is dependent upon the primary amino acid sequence and/or the conformation of ⁇ -Aminoadipate Reductase.
- TLC means thin layer chromatography.
- Transform refers to the introduction of a polynucleotide (single or double stranded DNA, RNA, or a combination thereof) into a living cell by any means. Transformation may be accomplished by a variety of methods, including, but not limited to, electroporation, polyethylene glycol mediated uptake, particle bombardment, agrotransformation, and the like. This process may result in transient or stable expression of the transformed polynucleotide.
- stably transformed is meant that the sequence of interest is integrated into a replicon in the cell, such as a chromosome or episome. Transformed cells encompass not only the end product of a transformation process, but also the progeny thereof which retain the polynucleotide of interest.
- transgenic refers to any cell, spore, tissue or part, that contains all or part of at least one recombinant polynucleotide. In many cases, all or part of the recombinant polynucleotide is stably integrated into a chromosome or stable extra-chromosomal element, so that it is passed on to successive generations.
- transposase refers to an enzyme that catalyzes transposition. Preferred transposons are described in WO 00/55346, PCT/US00/07317, and US 09/658859.
- transposition refers to a complex genetic rearrangement process involving the movement or copying of a polynucleotide (transposon) from one location and insertion into another, often within or between a genome or genomes, or DNA constructs such as plasmids, bacmids, and cosmids.
- transposon also known as a “transposable element”, “transposable genetic element”, “mobile element”, or “jumping gene” refers to a mobile DNA element such as those, for example, described in WO 00/55346, PCT/USOO/07317, and US 09/658859.
- Transposons can disrupt gene expression or cause deletions and inversions, and hence affect both the genotype and phenotype of the organisms concerned.
- the mobility of transposable elements has long been used in genetic manipulation, to introduce genes or other information into the genome of certain model systems.
- Tween 20 means sorbitan mono-9-octadecenoate poly(oxy- 1 , 1 -ethanediyl).
- viability of an organism refers to the ability of an organism to demonstrate growth under conditions appropriate for said organism, or to demonstrate an active cellular function. Some examples of active cellular functions include respiration as measured by gas evolution, secretion of proteins and/or other compounds, dye exclusion, mobility, dye oxidation, dye reduction, pigment production, changes in medium acidity, and the like.
- the present inventors have discovered that disruption of the AARl or HCSl gene and/or gene product inhibits the pathogenicity of Magnaporthe grisea.
- the inventors are the first to demonstrate that ⁇ -Aminoadipate Reductase and Homocitrate Synthase are targets for antibiotics, preferably antifungals.
- the invention provides methods for identifying compounds that inhibit AARl or HCSl gene expression or biological activity of its gene product(s). Such methods include ligand binding assays, assays for enzyme activity, cell-based assays, and assays for AARl or HSC1 gene expression. Any compound that is a ligand for ⁇ - Ammoadipate Reductase or for Homocitrate Synthase may have antibiotic activity.
- ligand refers to a molecule that will bind to a site on a polypeptide. The compounds identified by the methods of the invention are useful as antibiotics.
- the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising: a) contacting at least one polypeptide selected from the group consisting of: i) ⁇ -Aminoadipate Reductase; and ii) Homocitrate Synthase with said test compound; and b) detecting the presence or absence of binding between said test compound and said polypeptide; wherein binding indicates that said test compound is a candidate for an antibiotic.
- the ⁇ -Aminoadipate Reductase or Homocitrate Synthase protein may have the amino acid sequence of a naturally occurring ⁇ -Aminoadipate Reductase or Homocitrate Synthase found in a fungus, animal, plant, or microorganism, or may have an amino acid sequence derived from a naturally occurring sequence.
- the ⁇ - Aminoadipate Reductase or Homocitrate Synthase is a fungal ⁇ -Aminoadipate Reductase or Homocitrate Synthase.
- the cDNA (SEQ ID NO: 1) encoding the ⁇ - Aminoadipate Reductase protein, the genomic DNA (SEQ ID NO: 2) encoding the protein, and the polypeptide (SEQ ID NO: 3) can be found herein.
- the cDNA (SEQ ID NO: 4) encoding the Homocitrate Synthase protein, the genomic DNA (SEQ ID NO: 5) encoding the protein, and the polypeptide (SEQ ID NO: 6) can be found herein, as well.
- fungal ⁇ -Aminoadipate Reductase is meant an enzyme that can be found in at least one fungus, and which catalyzes the interconversion of L-2- Aminoadipate and NADPH and ATP with L-2 -Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H 2 O.
- the ⁇ -Aminoadipate Reductase may be from any of the fungi, including ascomycota, zygomycota, basidiomycota, chytridiomycota, and lichens.
- fungal Homocitrate Synthase an enzyme that can be found in at least one fungus, and which catalyzes the interconversion of acetyl-CoA and H 2 O and 2-oxoglutarate with 2-hydroxybutane-l,2,4-tricarboxylate and CoA.
- the homocitrate synthase may be from any of the fungi, including ascomycota, zygomycota, basidiomycota, chytridiomycota, and lichens.
- the ⁇ -Aminoadipate Reductase or Homocitrate Synthase is a Magnaporthe ⁇ -Aminoadipate Reductase or Homocitrate Synthase.
- Magnaporthe species include, but are not limited to, Magnaporthe rhizophila, Magnaporthe salvinii, Magnaporthe grisea and Magnaporthe poae and the imperfect states of Magnaporthe in the genus Pyricularia.
- the Magnaporthe ⁇ - Aminoadipate Reductase or Homocitrate Synthase is from Magnaporthe grisea.
- Synthase can be from Powdery Scab (Spongospora subterranea), Grey Mould (Bottytis cinered), White Rot (Armillaria melle ⁇ ), Heartrot Fungus (Ganoderma adspersum), Brown-Rot (Piptoporus betulinus), Corn Smut (Ustilago maydis), Heartrot (Polyporus squamosus), Gray Leaf Spot (Cercospora zeae-maydis), Honey Fungus (Armillaria gallica), Root rot (Armillaria luteobubalina), Shoestring Rot (Armillaria ostoyae), Banana Anthracnose Fungus (Colletotrichum musae), Apple- rotting Fungus (Monilinia fructigena), Apple-rotting Fungus (Penicillium expansum), Clubroot Disease (Plasmodiophora brassicae), Potato Blight (Phytophthora infestans), Root pathogen (Hetero
- Fragments of an ⁇ -Aminoadipate Reductase or Homocitrate Synthase polypeptide may be used in the methods of the invention, preferably if the fragments include an intact or nearly intact epitope that occurs on the biologically active wildtype ⁇ -Aminoadipate Reductase or Homocitrate Synthase.
- the fragments comprise at least 10 consecutive amino acids of an ⁇ -Aminoadipate Reductase or Homocitrate Synthase.
- the fragment comprises at least 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910,
- the fragment is from a Magnaporthe ⁇ - Ammoadipate Reductase or Homocitrate Synthase.
- the fragment contains an amino acid sequence conserved among fungal ⁇ -Aminoadipate Reductases or Homocitrate Synthases.
- sequence identity is at least 60%, more preferably the sequence identity is at least 70%, most preferably the sequence identity is at least 80%> or 90 or 95 or 99%, or any integer from 60-100%) sequence identity in ascending order.
- the polypeptide has at least 10%> of the activity of a fungal ⁇ -Aminoadipate Reductase or Homocitrate Synthase. More preferably, the polypeptide has at least 25%>, at least 50%o, at least 75% or at least 90%> of the activity of a fungal ⁇ -Aminoadipate Reductase or Homocitrate Synthase. Most preferably, the polypeptide has at least 10%>, at least 25%, at least 50%>, at least 75% or at least 90% of the activity of the grisea ⁇ -Aminoadipate Reductase or Homocitrate Synthase protein.
- the invention provides a method for identifying a test compound as a candidate for a fungicide, comprising: a) contacting said test compound with at least one polypeptide selected from the group consisting of: a polypeptide having at least ten consecutive amino acids of a fungal ⁇ -Aminoadipate Reductase, a polypeptide having at least 50% sequence identity with a fungal ⁇ -Aminoadipate Reductase, and a polypeptide having at least 10%> of the activity thereof; and b) detecting the presence and/or absence of binding between said test compound and said polypeptide; wherein binding indicates that said test compound is a candidate for an antibiotic.
- the invention provides a method for identifying a test compound as a candidate for a fungicide, comprising: a) contacting said test compound with at least one polypeptide selected from the group consisting of: a polypeptide having at least ten consecutive amino acids of a fungal homocitrate synthase, a polypeptide having at least 50% sequence identity with a fungal homocitrate synthase, and a polypeptide having at least 10%) of the activity thereof; and b) detecting the presence and/or absence of binding between said test compound and said polypeptide; wherein binding indicates that said test compound is a candidate for an antibiotic.
- Any technique for detecting the binding of a ligand to its target may be used in the methods of the invention.
- the ligand and target are combined in a buffer.
- Many methods for detecting the binding of a ligand to its target are known in the art, and include, but are not limited to the detection of an immobilized ligand- target complex or the detection of a change in the properties of a target when it is bound to a ligand.
- an array of immobilized candidate ligands is provided.
- the immobilized ligands are contacted with an ⁇ - Aminoadipate Reductase or Homocitrate Synthase protein or a fragment or variant thereof, the unbound protein is removed and the bound ⁇ -Aminoadipate Reductase is detected.
- bound ⁇ -Aminoadipate Reductase or Homocitrate Synthase is detected using a labeled binding partner, such as a labeled antibody.
- a labeled binding partner such as a labeled antibody.
- ⁇ -Aminoadipate Reductase or Homocitrate Synthase is labeled prior to contacting the immobilized candidate ligands.
- Preferred labels include fluorescent or radioactive moieties.
- Preferred detection methods include fluorescence correlation spectroscopy (FCS) and FCS-related confocal nanofluorimetric methods.
- a compound Once a compound is identified as a candidate for an antibiotic, it can be tested for the ability to inhibit ⁇ -Aminoadipate Reductase or Homocitrate Synthase enzymatic activity.
- the compounds can be tested using either in vitro or cell based assays.
- a compound can be tested by applying it directly to a fungus or fungal cell, or expressing it therein, and monitoring the fungus or fungal cell for changes or decreases in growth, development, viability, pathogenicity, or alterations in gene expression.
- the invention provides a method for determining whether a compound identified as an antibiotic candidate by an above method has antifungal activity, further comprising: contacting a fungus or fungal cells with said antifungal candidate and detecting a decrease in the growth, viability, or pathogenicity of said fungus or fungal cells.
- decrease in growth is meant that the antifungal candidate causes at least a 10% decrease in the growth of the fungus or fungal cells, as compared to the growth of the fungus or fungal cells in the absence of the antifungal candidate.
- a decrease in viability is meant that at least 20%> of the fungal cells, or portion of the fungus contacted with the antifungal candidate are nonviable.
- the growth or viability will be decreased by at least 40%>. More preferably, the growth or viability will be decreased by at least 50%, 75%> or at least 90%> or more. Methods for measuring fimgal growth and cell viability are known to those skilled in the art.
- the antifungal candidate causes at least a 10%> decrease in the disease caused by contact of the fungal pathogen with its host, as compared to the disease caused in the absence of the antifungal candidate.
- the disease will be decreased by at least 40%>. More preferably, the disease will be decreased by at least 50%>, 75%o or at least 90% or more.
- Methods for measuring fungal disease are well known to those skilled in the art, and include such metrics as lesion formation, lesion size, sporulation, respiratory failure, and/or death.
- ⁇ -Aminoadipate Reductase catalyzes the irreversible or reversible reaction
- L-2- Aminoadipate and NADPH and ATP L-2-Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H O (see Figure 1).
- Methods for detection of L-2-Aminoadipate, L-2-Aminoadipate 6-semialdehyde, NADP+, NADPH, AMP, ATP, H 2 O and/or pyrophosphate include spectrophotometry, mass spectroscopy, thin layer chromatography (TLC) and reverse phase HPLC.
- the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising either: a) contacting L-2 -Aminoadipate and NADPH and ATP with an ⁇ -Aminoadipate Reductase ; b) contacting L-2 -Aminoadipate and NADPH and ATP with ⁇ -Aminoadipate Reductase and said test compound; and c) determining the change in concentration for at least one of the following: L-2- Aminoadipate, L-2-Aminoadipate 6-semialdehyde, NADP+, NADPH, AMP, ATP, H 2 O and/or pyrophosphate.
- a change in concentration for any of the above substances indicates that said test compound is a candidate for an antibiotic, or, a) contacting L-2 -Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H 2 O with an ⁇ -Aminoadipate Reductase ; b) contacting L-2 -Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H 2 O with an ⁇ -Aminoadipate Reductase and said test compound; and c) determining the change in concentration for at least one of the following: L-2- Aminoadipate, L-2-Aminoadipate 6-semialdehyde, NADP+, NADPH, AMP,
- homocitrate synthase activity can be detected using in vitro enzymatic assays in which the disappearance of a substrate or the appearance of a product is directly or indirectly detected.
- Methods for detection of 2-hydroxybutane-l,2,4-tricarboxylate, CoA, acetyl-CoA, and/or 2-oxoglutarate include spectrophotometry, mass spectroscopy, thin layer chromatography (TLC) and reverse phase HPLC.
- the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising either: a) contacting acetyl-CoA and H 2 O and 2-oxoglutarate with a homocitrate synthase; b) contacting acetyl-CoA and H 2 O and 2-oxoglutarate with homocitrate synthase and said test compound; and c) determining the change in concentration for at least one of the following: 2- hydroxybutane-l,2,4-tricarboxylate, 2-oxoglutarate, acetyl-CoA, CoA, and/or H 2 O. wherein a change in concentration for any of the above substances indicates that said test compound is a candidate for an antibiotic.
- Enzymatically active fragments of a fungal ⁇ -Aminoadipate Reductase or Homocitrate Synthase are also useful in the methods of the invention.
- a polypeptide comprising at least 100 consecutive amino acid residues of a fungal ⁇ - Aminoadipate Reductase or Homocitrate Synthase maybe used in the methods of the invention, h addition, a polypeptide having at least 50%, 60%, 70%, 80%, 90%, 95% or at least 98%> sequence identity with a fungal ⁇ -Aminoadipate Reductase or Homocitrate Synthase may be used in the methods of the invention.
- the polypeptide has at least 50%> sequence identity with a fungal ⁇ -Aminoadipate Reductase or Homocitrate Synthase and at least 10%, 25%, 75%> or at least 90%> of the activity thereof.
- the invention provides a method for identifying a test compound as a candidate for a fungicide, comprising: a) contacting L-2-Aminoadipate and NADPH and ATP with a polypeptide selected from the group consisting of: a polypeptide having at least 50%> sequence identity with an ⁇ -Aminoadipate Reductase, a polypeptide having at least 50% > sequence identity with an ⁇ -Aminoadipate Reductase and having at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of an ⁇ -Aminoadipate Reductase b) contacting L-2 -Aminoadipate and NADPH and ATP with said polypeptide and said test compound; and c) determining the change in concentration for at least one of the following: L-2- Aminoadipate, L-2-Aminoadipate 6-semialdehyde, NADP+, NADPH, AMP,
- a change in concentration for any of the above substances indicates that said test compound is a candidate for an antibiotic, or, a) contacting L-2-Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H 2 O with a polypeptide selected from the group consisting of: a polypeptide having at least 50%> sequence identity with an ⁇ -Aminoadipate Reductase , a polypeptide having at least 50%> sequence identity with an ⁇ -Aminoadipate Reductase and at least 10%> of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of an ⁇ -Aminoadipate Reductase b) contacting L-2 -Aminoadipate 6-semialdehyde, NADP+, AMP, pyrophosphate, and H 2 O, with said polypeptide and said test compound; and c) determining the change
- the invention provides a method for identifying a test compound as a candidate for a fungicide, comprising: a) contacting acetyl-CoA and H O and 2-oxoglutarate with a polypeptide selected from the group consisting of: a polypeptide having at least 50%> sequence identity with a homocitrate synthase, a polypeptide having at least 50% sequence identity with a homocitrate synthase and having at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of a homocitrate synthase b) contacting acetyl-CoA and H O and 2-oxoglutarate with said polypeptide and said test compound; and c) determining the change in concentration for at least one of the following: 2- hydroxybutane-l,2,4-tricarboxylate, 2-oxoglutarate, acetyl-CoA, CoA, and/or H 2 O.
- a change in concentration for any of the above substances indicates that said test compound is a candidate for an antibiotic, or, a) contacting 2-hydroxybutane-l,2,4-tricarboxylate and CoA with a polypeptide selected from the group consisting of: a polypeptide having at least 50% sequence identity with a homocitrate synthase, a polypeptide having at least 50% sequence identity with a homocitrate synthase and at least 10% of the activity thereof, and a polypeptide comprising at least 100 consecutive amino acids of a homocitrate synthase b) contacting 2-hydroxybutane-l,2,4-tricarboxylate and CoA, with said polypeptide and said test compound; and c) determining the change in concentration for at least one of the following, 2- hydroxybutane-l,2,4-tricarboxylate, 2-oxoglutarate, acetyl-CoA, CoA, and/or
- ⁇ -Aminoadipate Reductase or Homocitrate Synthase protein and derivatives thereof may be purified from a fungus or may be recombinantly produced in and purified from an archael, bacterial, fungal, or other eukaryotic cell culture. Preferably these proteins are produced using an E. coli, yeast, or filamentous fungal expression system. Methods for the purification of ⁇ - Aminoadipate Reductase or Homocitrate Synthase may be described in Jaklitsch and Kubicek (Jaklitsch, W. M. and C. P.
- the invention also provides cell based assays.
- the invention provides a method for identifying a test compound as a candidate for a antibiotic, comprising: a) measuring the expression of an ⁇ -Aminoadipate Reductase or Homocitrate Synthase in a cell, cells, tissue, or an organism in the absence of said compound; b) contacting said cell, cells, tissue, or organism with said test compound and measuring the expression of said ⁇ -Aminoadipate Reductase or Homocitrate
- ⁇ -Aminoadipate Reductase or Homocitrate Synthase in said cell, cells, tissue, or organism; c) comparing the expression of ⁇ -Aminoadipate Reductase or Homocitrate Synthase in steps (a) and (b); wherein a lower expression in the presence of said test compound indicates that said compound is a candidate for an antibiotic.
- Expression of ⁇ -Aminoadipate Reductase or Homocitrate Synthase can be measured by detecting the AARl or HCS 1 primary transcript or mRNA, ⁇ -
- RNA and proteins are known to those skilled in the art. See, for example, Current Protocols in Molecular Biology Ausubel et al., eds., Greene Publishing and Wiley-Interscience, New York, 1995. The method of detection is not critical to the invention.
- Methods for detecting AARl RNA include, but are not limited to amplification assays such as quantitative reverse transcriptase-PCR, and/or hybridization assays such as Northern analysis, dot blots, slot blots, in-situ hybridization, transcriptional fusions using an AARl or HCSl promoter fused to a reporter gene, DNA assays, and microarray assays.
- amplification assays such as quantitative reverse transcriptase-PCR
- hybridization assays such as Northern analysis, dot blots, slot blots, in-situ hybridization, transcriptional fusions using an AARl or HCSl promoter fused to a reporter gene, DNA assays, and microarray assays.
- Methods for detecting protein expression include, but are not limited to, immunodetection methods such as Western blots, ELISA assays, polyacrylamide gel electrophoresis, mass spectroscopy, and enzymatic assays.
- any reporter gene system may be used to detect AARl or HCSl protein expression.
- a polynucleotide encoding a reporter protein is fused in frame with AARl or HCSl, so as to produce a chimeric polypeptide. Methods for using reporter systems are known to those skilled in the art.
- Chemicals, compounds or compositions identified by the above methods as modulators, preferably inhibitors, of AARl or HCSl expression or activity can then be used to control fungal growth. Diseases such as rusts, mildews, and blights spread rapidly once established. Fungicides are thus routinely applied to growing and stored crops as a preventive measure, generally as foliar sprays or seed dressings.
- a preventive measure generally as foliar sprays or seed dressings.
- compounds that inhibit fungal growth can be applied to a fungus or expressed in a fungus, in order to prevent fungal growth.
- the invention provides a method for inhibiting fungal growth, comprising contacting a fungus with a compound identified by the methods of the invention as having antifungal activity.
- Antifungals and antifungal inhibitor candidates identified by the methods of the invention can be used to control the growth of undesired fungi, including ascomycota, zygomycota, basidiomycota, chytridiomycota, and lichens.
- undesired fungi include, but are not limited to Powdery Scab (Spongospora subterranea), Grey Mould (Botrytis cinerea), White Rot (Armillaria melled), Heartrot Fungus (Ganoderma adspersum), Brown-Rot (Piptoporus betulinus), Corn Smut (Ustilago maydis), Heartrot (Polyporus squamosus), Gray Leaf Spot (Cercospora zeae-maydis), Honey Fungus (Armillaria gallica), Root rot (Armillaria luteobubalina), Shoestring Rot (Armillaria ostoyae), Banana Anthracnose Fungus (Colletotrichum musae), Apple-rotting Fungus (Moniliniafructigena), Apple- rotting Fungus (Penicillium expansum), Clubroot Disease (Plasmodiophora brassicae), Potato Blight (Phytophthora infestans),
- the method is performed by providing an organism having a first form of the gene corresponding to either SEQ ED NO: 1 or SEQ ED NO: 2 for AARl, or SEQ ED NO: 4 and SEQ ED NO: 5 for HCSl, either a normal form, a mutant form, a homologue, or a heterologous AARl or HCSl gene that performs a similar function as AARl or HCSl, respectively.
- the first form of AARl or HCSl may or may not confer a growth conditional phenotype, i.e., a lysine requiring phenotype, and/or a hypersensitivity or hyposensitivity phenotype on the organism having that altered form.
- a mutant form contains a transposon insertion.
- a comparison organism having a second form of an AARl or HCSl, different from the first form of the gene is also provided, and the two organisms are separately contacted with a test compound. The growth of the two AARl or HCSl organisms in the presence of the test compound is then compared.
- the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising: a) providing cells having one form of an ⁇ -Aminoadipate Reductase gene, and providing comparison cells having a different form of an ⁇ -Aminoadipate
- Reductase gene b) contacting said cells and said comparison cells with a test compound and determining the growth of said cells and comparison cells in the presence of the test compound, wherein a difference in growth between said cells and said comparison cells in the presence of said test compound indicates that said test compound is a candidate for an antibiotic.
- the invention provides a method for identifying a test compound as a candidate for an antibiotic, comprising: a) providing cells having one form of a Homocitrate Synthase gene, and providing comparison cells having a different form of a Homocitrate Synthase gene, b) contacting said cells and said comparison cells with a test compound and determining the growth of said cells and comparison cells in the presence of the test compound, wherein a difference in growth between said cells and said comparison cells in the presence of said test compound indicates that said test compound is a candidate for an antibiotic.
- the optional determination of the growth of said first organism and said comparison second organism in the absence of any test compounds may be performed to control for any inherent differences in growth as a result of the different genes. It is also recognized that any combination of two different forms of an AARl gene or an HCSl gene, including normal genes, mutant genes, homologues, and functional homologues may be used in this method. Growth and/or proliferation of an organism is measured by methods well known in the art such as optical density measurements, and the like. In a preferred embodiment the organism is Magnaporthe grisea.
- Conditional lethal mutants may identify particular biochemical and/or genetic pathways given that at least one identified target gene is present in that pathway. Knowledge of these pathways allows for the screening of test compounds as candidates for antibiotics as inhibitors of the substrates, products and enzymes of the pathway. Pathways known in the art may be found at the Kyoto Encyclopedia of Genes and Genomes and in standard biochemistry texts (Lehninger, A., D. Nelson, et al. (1993) Principles of Biochemistry. New York, Worth Publishers).
- the invention provides a method for screening for test compounds acting against the biochemical and/or genetic pathway or pathways in which AARl or HCSl functions, comprising: a) providing cells having one form of a gene in the lysine biochemical and/or genetic pathway and providing comparison cells having a different form of said gene; b) contacting said cells and comparison cells with a said test compound; and c) determining the growth of said cells and comparison cells in the presence of said test compound, wherein a difference in growth between said cells and said comparison cells in the presence of said compound indicates that said compound is a candidate for an antibiotic.
- multi- well plates for screening is a format that readily accommodates multiple different assays to characterize various compounds, concentrations of compounds, and fungal strains in varying combinations and formats.
- Certain testing parameters for the screening method can significantly affect the identification of growth inhibitors, and thus can be manipulated to optimize screening efficiency and/or reliability. Notable among these factors are variable sensitivities of different mutants, increasing hypersensitivity with increasingly less permissive conditions, an apparent increase in hypersensitivity with increasing compound concentration, and other factors known to those in the art.
- Conditional lethal mutants may identify particular biochemical and/or genetic pathways given that at least one identified target gene is present in that pathway. Knowledge of these pathways allows for the screening of test compounds as candidates for antibiotics. Pathways known in the art may be found at the Kyoto Encyclopedia of Genes and Genomes and in standard biochemistry texts (Lehninger, A., D. Nelson, et al. (1993) Principles of Biochemistry. New York, Worth Publishers). Thus, in one embodiment, the invention provides a method for screening for test compounds acting against the biochemical and/or genetic pathway or pathways in which AARl or HCSl functions, comprising:
- paired growth media comprising a first medium and a second medium, wherein said second medium contains a higher level of lysine than said first medium;
- Sif transposon was constructed using the GPS3 vector from the GPS-M mutagenesis system from New England Biolabs, Inc. (Beverly, MA) as a backbone. This system is based on the bacterial transposon Tn7. The following manipulations were done to GPS3 according to Sambrook et al. (1989) Molecular Cloning, a Laboratorv Manual, Cold Spring Harbor Laboratory Press. The kanamycin resistance gene (npt) contained between the Tn7 arms was removed by EcoRV digestion.
- hph The bacterial hygromycin B phosphotransferase (hph) gene (Gritz and Davies (1983) Gene 25: 179 - 88 (PMED: 6319235)) under confrol of ' the Aspergillus nidulans trpC promoter and terminator (Mullaney et al. (1985) Mol Gen Genet 199: 37 - 45 (PMED: 3158796)) was cloned by a Hpal/EcoRN blunt ligation into the Tn7 arms of the GPS3 vector yielding pSifl .
- Cosmid libraries were constructed in the pcosKA5 vector (Hamer et al. (2001)
- Transformation of Topi OF' electrocompetent cells was done according to manufacturers recommendations. Sif-containing cosmid transformants were selected by growth on LB agar plates containing 50ug/ml of hygromycin B (Sigma Chem. Co.) and 100 ug/ml of Ampicillin (Sigma Chem. Co.).
- E. coli strains containing cosmids with transposon insertions were picked to 96 well growth blocks (Beckman Co.) containing 1.5 ml of TB (Terrific Broth,
- Cosmid DNA from the AARl transposon tagged cosmid clone was prepared using QIAGEN Plasmid Maxi Kit (QIAGEN), and digested by PI-PspI (New England Biolabs, Inc.). Fungal electro-transformation was performed essentially as described (Wu et al. (1997) MPMI 10: 700 - 708). Briefly, M. grisea strain Guy 11 was grown in complete liquid media (Talbot et al. (1993) Plant Cell 5: 1575 - 1590 (PMID:
- Transformed protoplasts were regenerated in complete agar media (CM, Talbot et al. (1993) Plant Cell 5: 1575 - 1590 (PMED: 8312740)) with the addition of 20%> sucrose for one day, then overlayed with CM agar media containing hygromycin B (250ug/ml) to select transformants.
- CM complete agar media
- hygromycin B 250ug/ml
- Transformants were screened for homologous recombination events in the target gene by PCR (Hamer et al. (2001) Proc Natl Acad Sci USA 98: 5110 - 15 (PMID: 11296265)). Two independent strains were identified for AARl and are hereby referred to as KOl-1 and KOl-11, respectively. For HCSl, two independent strains were also identified and are hereby referred to as HCSl KOl-1 and KO1-2, respectively.
- Rice infection assays were performed using Indian rice cultivar CO39 essentially as described in Nalent et al. ((1991) Genetics 127: 87 - 101 (PMED: 2016048)). All three strains were grown for spore production on complete agar media. Spores were harvested and the concentration of spores adjusted for whole plant inoculations.
- the fungal strains, KOl-1 and KOl-11, containing the AARl disrupted gene obtained in Example 5 were analyzed for their nutritional requirement for lysine using the PM5 phenotype microarray from Biolog, Inc. (Hayward, CA).
- the PM5 plate tests for the auxotrophic requirement for 94 different metabolites.
- the inoculating fluid consists of 0.05% Phytagel, 0.03%o Pluronic F68, 1% glucose, 23.5mM NaNO 3 , 6.7mM KCl, 3.5mM Na 2 SO 4 , 1 ImM KH 2 PO 4 , 0.01% 7-iodonitrotetrazolium violet, O.lmM MgCl 2 , OmM CaCl 2 and trace elements.
- Final concentrations of trace elements are: 7.6 ⁇ M ZnCl 2 , 2.5 ⁇ M MnCl 2 4H 2 0, 1.8 ⁇ M FeCl 2 4H 2 O, 0.71 ⁇ M CoCl 2 6H 2 O, 0.64 ⁇ M CuCl 2 2H 2 O, 0.62 ⁇ M Na 2 MoO 4 , 18 ⁇ M H 3 BO 3 . pH adjusted to 6.0 with NaOH. Spores for each strain were harvested into the inoculating fluid. The spore concentrations were adjusted to 2xl0 5 spores/ml. lOO ⁇ l of spore suspension were deposited into each well of the microtiter plates. The plates were incubated at 25°C for 7 days.
- Optical density (OD) measurements at 490nm and 750nm were taken daily.
- the OD 490 measures the extent of tetrazolium dye reduction and the level of growth, and OD 750 measures growth only.
- Turbidity OD 490 + OD 50 .
- Data confirming the annotated gene function is presented as a graph of Turbidity vs. Time showing both the mutant fungi and the wild-type control in the absence ( Figure 3A) and presence ( Figure 3B) of L-lysine.
- Rice infection assays were performed using Indian rice cultivar CO39 essentially as described in Valent et al. ((1991) Genetics 127: 87 - 101 (PMED: 2016048)). All three strains were grown for spore production on complete agar media. Spores were harvested and the concentration of spores adjusted for whole plant inoculations.
- the fungal strains, KOl-1 and KOI -2, containing the HCSl disrupted gene obtained in Example 5 were analyzed for their nutritional requirement for lysine using the PM5 phenotype microarray from Biolog, Inc. (Hayward, CA).
- the inoculating fluid consists of 0.05% Phytagel, 0.03% Pluronic F68, 1% glucose, 23.5mM NaNO 3 , 6.7mM KCl, 3.5mM Na 2 SO , 1 ImM KH 2 PO 4 , O.O /o ⁇ -iodonitrotetrazolium violet, O.lmM MgCl 2 , OmM CaCl 2 and trace elements.
- Final concentrations of trace elements are: 7.6 ⁇ M ZnCl 2 , 2.5 ⁇ M MnCl 2 4H 2 0, 1.8 ⁇ M FeCl 2 4H 2 O, 0.71 ⁇ M CoCl 2 6H2O, 0.64 ⁇ M CuCl 2 ' 2H 2 O, 0.62 ⁇ M Na 2 MoO 4 , 18 ⁇ M H 3 BO 3 . pH adjusted to 6.0 with NaOH. Spores for each strain were harvested into the inoculating fluid. The spore concentrations were adjusted to 2xl0 5 spores/ml. lOO ⁇ l of spore suspension were deposited into each well of the microtiter plates. The plates were incubated at 25°C for 7 days.
- Optical density (OD) measurements at 490nm and 750nm were taken daily.
- the OD 490 measures the extent of tetrazolium dye reduction and the level of growth, and OD 75 Q measures growth only.
- Turbidity OD 4 0 + OD 750 .
- Data confirming the annotated gene function is presented as a graph of Turbidity vs. Time showing both the mutant fungi and the wild-type control in the absence ( Figure 6A) and presence ( Figure 6B) of L-lysine.
- the following protocol may be employed to obtain a purified ⁇ -Aminoadipate Reductase protein.
- the following protocol may be employed to identify test compounds that bind to the ⁇ -Aminoadipate Reductase or Homocitrate Synthase protein.
- Buffer conditions are optimized (e.g. ionic strength or pH, Jaklitsch, W. M. and C. P. Kubicek (1990) Biochem J 269: 247 - 53 (PMED: 2115771)) for binding of radiolabeled 14 C- ⁇ -Aminoadipic acid (Sigma-Aldrich Co.) to the bound AARl, or for binding of radiolabeled (acetyl-l- 14 C)- coenzyme A (Sigma-Aldrich Co.) to the bound HCSl.
- ionic strength or pH Jaklitsch, W. M. and C. P. Kubicek (1990) Biochem J 269: 247 - 53 (PMED: 2115771)
- test compound • Screening of test compounds is performed by adding test compound and 14 C- ⁇ -Aminoadipic acid (Sigma-Aldrich Co.) to the wells of the HisGrabTM plate containing bound AARl , or performed by adding test compound and (acetyl- l- 14 C)-coenzyme A (Sigma-Aldrich Co.) to the wells of the HisGrabTM plate containing bound HCSl.
- 14 C- ⁇ -Aminoadipic acid Sigma-Aldrich Co.
- Candidate compounds are identified as wells with lower radioactivity as compared to control wells with no test compound added.
- a purified polypeptide comprising 10-50 amino acids from the M. grisea ⁇ -Aminoadipate Reductase or Homocitrate Synthase is screened in the same way.
- a polypeptide comprising 10-50 amino acids is generated by subcloning a portion of the AARl or HCSl gene into a protein expression vector that adds a His- Tag when expressed (see Example 8).
- Oligonucleotide primers are designed to amplify a portion of the AARl or HCSl gene using the polymerase chain reaction amplification method.
- the DNA fragment encoding a polypeptide of 10-50 amino acids is cloned into an expression vector, expressed in a host organism and purified as described in Example 10 above.
- Test compounds that bind AARl or HCSl are further tested for antibiotic activity.
- M. grisea is grown as described for spore production on oatmeal agar media (Talbot et al. (1993) Plant Cell 5: 1575 - 1590 (PMED: 8312740)). Spores are harvested into minimal media (Talbot et al. (1993) Plant Cell 5: 1575 - 1590 (PMED: 8312740)) to a concenfration of 2 x 10 5 spores/ml and the culture is divided. The test compound is added to one culture to a final concentration of 20-100 ⁇ g/ml. Solvent only is added to the second culture.
- test compound is an antibiotic candidate if the growth of the culture containing the test compound is less than the growth of the control culture.
- Synthase is determined in the presence and absence of candidate compounds in a suitable reaction mixture, such as described by Gray and Bhattacharjee (Gray, GS and Bhattacharjee, JK (1976) Can J Microbiol 22: 1664 - 7 (PMED: 10066)), or Jaklitsch, W. M. and C. P. Kubicek (1990) Biochem J 269: 247 - 53 (PMJD: 2115771).
- Candidate compounds are identified when a decrease in products or a lack of decrease in substrates is detected with the reaction proceeding in either direction.
- the enzymatic activity of a polypeptide comprising 10-50 amino acids from the M. grisea ⁇ -Aminoadipate Reductase or Homocitrate Synthase is determined in the presence and absence of candidate compounds in a suitable reaction mixture, such as described by Gray and Bhattacharjee (Gray, GS and Bhattacharjee, JK (1976) Can J Microbiol 22: 1664 - 7 (PMED: 10066)), or Jaklitsch, W. M. and C. P. Kubicek (1990) Biochem J 269: 247 - 53 (PMED: 2115771).
- a polypeptide comprising 10-50 amino acids is generated by subcloning a portion of the AARl or HCSl gene into a protein expression vector that adds a His-Tag when expressed (see Example 10).
- Oligonucleotide primers are designed to amplify a portion of the AARl or HCSl gene using polymerase chain reaction amplification method.
- the DNA fragment encoding a polypeptide of 10-50 amino acids is cloned into an expression vector, expressed and purified as described in Example 10 above.
- Test compounds identified as inhibitors of AARl or HCSl activity are further tested for antibiotic activity.
- Magnaporthe grisea fungal cells are grown under standard fungal growth conditions that are well known and described in the art.
- M. grisea is grown as described for spore production on oatmeal agar media (Talbot et al. (1993) Plant Cell 5: 1575 - 1590 (PMED: 8312740)). Spores are harvested into minimal media (Talbot et al. (1993) Plant Cell 5: 1575 - 1590 (PMID: 8312740)) to a concentration of 2 x IO 5 spores/ml and the culture is divided. The test compound is added to one culture to a final concentration of 20-100 ⁇ g/ml.
- Solvent only is added to the second culture.
- the plates are incubated at 25°C for seven days and optical density measurements at 590nm are taken daily.
- the growth curves of the solvent control sample and the test compound sample are compared.
- a test compound is an antibiotic candidate if the growth of the culture containing the test compound is less than the growth of the control culture.
- Magnaporthe grisea fungal cells are grown under standard fungal growth conditions that are well known and described in the art. Wild-type M. grisea spores are harvested from cultures grown on complete agar or oatmeal agar media after growth for 10-13 days in the light at 25°C using a moistened cotton swab. The concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium to a concentration of 2x10 5 spores per ml. 25 ml cultures are prepared to which test compounds will be added at various concentrations. A culture with no test compound present is included as a control. The cultures are incubated at 25°C for 3 days after which test compound or solvent only control is added.
- RNA samples are incubated an additional 18 hours. Fungal mycelia is harvested by filtration through Miracloth (CalBiochem®, La Jolla, CA), washed with water and frozen in liquid nitrogen. Total RNA is extracted with TRIZOL® Reagent using the methods provided by the manufacturer (Life Technologies, Rockville, MD). Expression is analyzed by Northern analysis of the RNA samples as described (Sambrook et al. (1989) Molecular Cloning, a Laboratorv Manual, Cold Spring Harbor Laboratory Press) using a radiolabeled fragment of the AARl or HCSl gene as a probe. Test compounds resulting in a reduced level of AARl or HCSl mRNA relative to the untreated control sample are identified as candidate antibiotic compounds.
- Magnaporthe grisea fungal cells containing a mutant form of the AARl or HCSl gene which abolishes enzyme activity, such as a gene containing a transposon insertion (see Examples 4 and 5), are grown under standard fungal growth conditions that are well known and described in the art.
- Magnaporthe grisea spores are harvested from cultures grown on complete agar medium containing 4mM L-lysine (Sigma-Aldrich Co.) after growth for 10-13 days in the light at 25°C using a moistened cotton swab.
- the concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium containing 100 ⁇ M L-lysine to a concentration of 2x10 5 spores per ml. Approximately 4xl0 4 spores are added to each well of 96-well plates to which a test compound is added (at varying concentrations). The total volume in each well is 200 ⁇ l. Wells with no test compound present (growth control), and wells without cells are included as controls (negative control). The plates are incubated at 25°C for seven days and optical density measurements at 590nm are taken daily. Wild type cells are screened under the same conditions.
- Example 15 In Vivo Cell Based Assay Screening Protocol with a Fungal Strain Containing a Mutant Form of ⁇ -Aminoadipate Reductase or Homocitrate Synthase with Reduced Activity
- Magnaporthe grisea fungal cells containing a mutant form of the AARl or HCSl gene, such as a promoter truncation that reduces expression, are grown under standard fungal growth conditions that are well known and described in the art.
- a promoter truncation is made by deleting a portion of the promoter upstream of the transcription start site using standard molecular biology techniques that are well known and described in the art (Sambrook et al. (1989) Molecular Cloning, a Laboratorv Manual, Cold Spring Harbor Laboratory Press).
- Magnaporthe grisea spores are harvested from cultures grown on complete agar medium containing 4mM L-lysine (Sigma-Aldrich Co.) after growth for 10-13 days in the light at 25°C using a moistened cotton swab.
- the concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium to a concentration of 2x10 5 spores per ml.
- Approximately 4xl0 4 spores are added to each well of 96-well plates to which a test compound is added (at varying concentrations). The total volume in each well is 200 ⁇ l. Wells with no test compound present (growth control), and wells without cells are included as controls (negative control).
- the plates are incubated at 25°C for seven days and optical density measurements at 590nm are taken daily. Wild type cells are screened under the same conditions. The effect of each compound on the mutant and wild-type fungal strains is measured against the growth control and the percent of inhibition is calculated as the OD 590 (fungal strain plus test compound) / OD 590 (growth control) x 100. The percent of growth inhibition as a result of a test compound on a fungal strain and that on the wild-type cells are compared. Compounds that show differential growth inhibition between the mutant and the wild type are identified as potential antifungal compounds. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 11 - 221 (PMED: 7749303)).
- Magnaporthe grisea fungal cells containing a mutant form of a gene in the lysine biosynthetic pathway are grown under standard fungal growth conditions that are well known and described in the art.
- Magnaporthe grisea spores are harvested from cultures grown on complete agar medium containing 4mM L-lysine (Sigma-Aldrich Co.) after growth for 10-13 days in the light at 25°C using a moistened cotton swab.
- the concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium containing 100 ⁇ M L-lysine to a concenfration of 2x10 5 spores per ml. Approximately 4xl0 4 spores or cells are harvested and added to each well of 96-well plates to which growth media is added in addition to an amount of test compound (at varying concentrations). The total volume in each well is 200 ⁇ l. Wells with no test compound present, and wells without cells are included as controls. The plates are incubated at 25°C for seven days and optical density measurements at 590nm are taken daily. Wild type cells are screened under the same conditions.
- Example 17 In Vivo Cell Based Assay Screening Protocol with a Fungal Strain Containing a Mutant Form of a Lysine Biosynthetic Gene with Reduced Activity
- Magnaporthe grisea fungal cells containing a mutant form of a gene in the lysine biosynthetic pathway (e.g. HCSl (E.C. 4.1.3.21)), such as a promoter truncation that reduces expression, are grown under standard fungal growth conditions that are well known and described in the art.
- a promoter truncation is made by deleting a portion of the promoter upstream of the transcription start site using standard molecular biology techniques that are well known and described in the art (Sambrook et al. (1989) Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory Press).
- Magnaporthe grisea fungal cells containing a mutant form of are grown under standard fungal growth conditions that are well known and described in the art.
- Magnaporthe grisea spores are harvested from cultures grown on complete agar medium containing 4mM L-lysine (Sigma-Aldrich Co.) after growth for 10-13 days in the light at 25°C using a moistened cotton swab.
- the concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium to a concentration of 2x10 5 spores per ml.
- Approximately 4x10 4 spores or cells are harvested and added to each well of 96-well plates to which growth media is added in addition to an amount of test compound (at varying concentrations). The total volume in each well is 200 ⁇ l.
- Wild-type Magnaporthe grisea fungal cells and M. grisea fungal cells lacking a functional AARl gene and containing an AARl gene from Penicillium chrysogenum are grown under standard fungal growth conditions that are well known and described in the art.
- An M. grisea strain carrying a heterologous AARl gene is made as follows:
- An M. grisea strain is made with a nonfunctional AARl gene, such as one containing a transposon insertion in the native gene (see Examples 4 and 5).
- a construct containing a heterologous AARl gene is made by cloning the AARl gene from Penicillium chrysogenum into a fungal expression vector containing a trpC promoter and terminator (e.g. pCB1003, Carroll et al. (1994) Fungal Gen
- the said construct is used to transform the M. grisea strain lacking a functional AARl gene (see Example 5). Transformants are selected on minimal agar medium lacking L-lysine. Only transformants carrying a functional AARl gene will grow.
- Wild-type strains of Magnaporthe grisea and strains containing a heterologous form of AARl are grown under standard fungal growth conditions that are well known and described in the art.
- Magnaporthe grisea spores are harvested from cultures grown on complete agar medium after growth for 10-13 days in the light at 25°C using a moistened cotton swab.
- the concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium to a concentration of 2x10 5 spores per ml.
- Approximately 4xl0 4 spores or cells are harvested and added to each well of 96-well plates to which growth media is added in addition to an amount of test compound (at varying concentrations).
- the total volume in each well is 200 ⁇ l. Wells with no test compound present, and wells without cells are included as controls. The plates are incubated at 25°C for seven days and optical density measurements at 590nm are taken daily. The effect of each compound on the wild-type and heterologous fungal strains is measured against the growth control and the percent of inhibition is calculated as the OD 59 o (fungal strain plus test compound) / OD 590 (growth control) x 100. The percent of growth inhibition as a result of a test compound on the wild-type and heterologous fungal strains are compared. Compounds that show differential growth inhibition between the wild-type and heterologous strains are identified as potential antifungal compounds with specificity to the native or heterologous AARl gene products. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 111 - 221 (PMED: 7749303)).
- Wild-type Magnaporthe grisea fungal cells and M. grisea fungal cells lacking a functional HCSl gene and containing a HCSl gene from Thermus aquaticus are grown under standard, fungal growth conditions that are well known and described in the art.
- An M. grisea strain canying a heterologous HCSl gene is made as follows: • An M. grisea strain is made with a nonfunctional HCSl gene, such as one containing a transposon insertion in the native gene (see Examples 4 and 5).
- a construct containing a heterologous HCSl gene is made by cloning the HCSl gene from Thermus aquaticus into a fungal expression vector containing a trpC promoter and terminator (e.g. pCB1003, Carroll et al. (1994) Fungal Gen News Lett 41 : 22) using standard molecular biology techniques that are well known and described in the art (Sambrook et al. (1989) Molecular Cloning, a Laboratorv Manual, Cold Spring Harbor Laboratory Press).
- the said construct is used to transform the M. grisea strain lacking a functional HCSl gene (see Example 5). Transformants are selected on minimal agar medium lacking L-lysine. Only transformants carrying a functional HCSl gene will grow.
- Wild-type strains of Magnaporthe grisea and strains containing a heterologous form of HCSl are grown under standard fungal growth conditions that are well known and described in the art.
- Magnaporthe grisea spores are harvested from cultures grown on complete agar medium after growth for 10-13 days in the light at 25°C using a moistened cotton swab.
- the concentration of spores is determined using a hemacytometer and spore suspensions are prepared in a minimal growth medium to a concentration of 2x10 5 spores per ml.
- Approximately 4xl0 4 spores or cells are harvested and added to each well of 96-well plates to which growth media is added in addition to an amount of test compound (at varying concentrations).
- the total volume in each well is 200 ⁇ l. Wells with no test compound present, and wells without cells are included as controls. The plates are incubated at 25°C for seven days and optical density measurements at 590nm are taken daily. The effect of each compound on the wild-type and heterologous fungal strains is measured against the growth control and the percent of inhibition is calculated as the ODsgo (fungal strain plus test compound) / OD 590 (growth control) x 100. The percent of growth inhibition as a result of a test compound on the wild-type and heterologous fungal strains are compared. Compounds that show differential growth inhibition between the wild-type and heterologous strains are identified as potential antifungal compounds with specificity to the native or heterologous HCSl gene products. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 177 - 221 (PMED: 7749303)).
- Magnaporthe grisea fungal cells are grown under standard fungal growth conditions that are well known and described in the art. Wild-type M. grisea spores are harvested from cultures grown on oatmeal agar media after growth for 10-13 days in the light at 25°C using a moistened cotton swab. The concentration of spores is determined using a hemocytometer and spore suspensions are prepared in a minimal growth medium and a minimal growth medium containing 4mM L-lysine (Sigma- Aldrich Co.) to a concentration of 2xl0 5 spores per ml.
- the minimal growth media contains carbon, nitrogen, phosphate, and sulfate sources, and magnesium, calcium, and trace elements (for example, see inoculating fluid in Example 7).
- Spore suspensions are added to each well of a 96-well microtiter plate (approximately 4xl0 4 spores/well).
- an additional well is present containing a spore suspension in minimal medium containing 4mM L-lysine.
- Test compounds are added to wells containing spores in minimal media and minimal media containing L-lysine. The total volume in each well is 200 ⁇ l. Both minimal media and L-lysine containing media wells with no test compound are provided as controls.
- a compound is identified as a candidate for an antibiotic acting against the lysine biosynthetic pathway when the observed growth in the well containing minimal media is less than the observed growth in the well containing L-lysine as a result of the addition of the test compound. Similar protocols may be found in Kirsch and DiDomenico ((1994) Biotechnology 26: 111 - 221 (PMED: 7749303)).
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002365038A AU2002365038A1 (en) | 2001-11-09 | 2002-11-12 | Methods for the identification of inhibitors of alpha-aminoadipate reductase and homocitrate synthase as antibiotics |
EP02803979A EP1481080A4 (en) | 2001-11-09 | 2002-11-12 | Methods for the identification of inhibitors of alpha-aminoadipate reductase and homocitrate synthase as antibiotics |
JP2003547565A JP2005510230A (en) | 2001-11-09 | 2002-11-12 | Methods for identifying inhibitors of alpha-aminoadipate reductase and homocitrate synthase as antibiotics |
CA002469772A CA2469772A1 (en) | 2001-11-09 | 2002-11-12 | Methods for the identification of inhibitors of alpha-aminoadipate reductase and homocitrate synthase as antibiotics |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/011,200 US6632631B1 (en) | 2001-11-09 | 2001-11-09 | Methods for the identification of inhibitors of homocitrate synthase as antibiotics |
US10/011,146 US6723529B2 (en) | 2001-11-09 | 2001-11-09 | Methods for the identification of inhibitors of α-aminoadipate reductase as antibiotics |
US10/011,200 | 2001-11-09 | ||
US10/011,146 | 2001-11-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003046130A2 true WO2003046130A2 (en) | 2003-06-05 |
WO2003046130A3 WO2003046130A3 (en) | 2004-09-16 |
Family
ID=26682060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/036508 WO2003046130A2 (en) | 2001-11-09 | 2002-11-12 | Methods for the identification of inhibitors of alpha-aminoadipate reductase and homocitrate synthase as antibiotics |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1481080A4 (en) |
JP (1) | JP2005510230A (en) |
AU (1) | AU2002365038A1 (en) |
CA (1) | CA2469772A1 (en) |
WO (1) | WO2003046130A2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000000643A2 (en) * | 1998-06-29 | 2000-01-06 | Miami University | Methods and reagents for detecting fungal pathogens in a biological sample |
-
2002
- 2002-11-12 AU AU2002365038A patent/AU2002365038A1/en not_active Abandoned
- 2002-11-12 WO PCT/US2002/036508 patent/WO2003046130A2/en not_active Application Discontinuation
- 2002-11-12 CA CA002469772A patent/CA2469772A1/en not_active Abandoned
- 2002-11-12 EP EP02803979A patent/EP1481080A4/en not_active Withdrawn
- 2002-11-12 JP JP2003547565A patent/JP2005510230A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000000643A2 (en) * | 1998-06-29 | 2000-01-06 | Miami University | Methods and reagents for detecting fungal pathogens in a biological sample |
Non-Patent Citations (1)
Title |
---|
See also references of EP1481080A2 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002365038A1 (en) | 2003-06-10 |
AU2002365038A8 (en) | 2003-06-10 |
CA2469772A1 (en) | 2003-06-05 |
EP1481080A4 (en) | 2006-02-22 |
JP2005510230A (en) | 2005-04-21 |
WO2003046130A3 (en) | 2004-09-16 |
EP1481080A2 (en) | 2004-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6632631B1 (en) | Methods for the identification of inhibitors of homocitrate synthase as antibiotics | |
US6689578B2 (en) | Methods for the identification of inhibitors of 5-aminolevulinate synthase as antibiotics | |
US6723529B2 (en) | Methods for the identification of inhibitors of α-aminoadipate reductase as antibiotics | |
US20050227304A1 (en) | Methods for the identification of inhibitors of histidinol dehydrogenase as antibiotics | |
US6806060B2 (en) | Methods for the identification of inhibitors of threonine synthase as antibiotics | |
US6740498B2 (en) | Methods for the identification of inhibitors of histidinol-phosphate as antibiotics | |
US6733963B2 (en) | Methods for the identification of inhibitors of 3-isopropylmalate dehydratase as antibiotics | |
US6852484B2 (en) | Methods for the identification of inhibitors of asparagine synthase as antibiotics | |
US20050019846A1 (en) | Methods for the identification of inhibitors of ornithine carbamoyltransferase as antibiotics | |
US20040146960A1 (en) | Methods for the identification of inhibitors of Trehalose-6-Phosphate Synthase as antibiotics | |
US20030224472A1 (en) | Methods for the identification of inhibitors of putrescine aminopropyltransferase as antibiotics | |
US20030228650A1 (en) | Methods for the identification of inhibitors of Methylenetetrahydrofolate reductase as antibiotics | |
US20050048593A1 (en) | Methods for the identification of inhibitors of acetolactate synthase as antibiotics | |
US20030224970A1 (en) | Methods for the identification of inhibitors of S-adenosylmethionine decarboxylase as antibiotics | |
WO2003046130A2 (en) | Methods for the identification of inhibitors of alpha-aminoadipate reductase and homocitrate synthase as antibiotics | |
US20040248773A1 (en) | Methods for the identification of inhibitors of pyrroline-5-carboxylate reductase as antibiotics | |
US20050042706A1 (en) | Methods for the identification of inhibitors of porphobilinogen deaminase as antibiotics | |
EP1581795A2 (en) | Methods for the identification of inhibitors of chitin synthase 2, s-adenosylmethionine decarboxylase, putrescine aminopropyltransferase, and methylenete trahydrofolate reductase as antibiotics | |
US20050221409A1 (en) | Methods for the identification of inhibitors of amidophosphoribosyltransferase as antibiotics | |
US20050227305A1 (en) | Methods for the identification of inhibitors of adenylosuccinate synthase as antibiotics | |
US20030228645A1 (en) | Methods for the identification of inhibitors of chitin synthase 2 as antibiotics | |
US20050042705A1 (en) | Methods for the identification of inhibitors of mannosyltransferase as antibiotics | |
EP1461460A2 (en) | Methods for the identification of inhibitors of asparagine synthase, 5-aminolevulinate synthase, histidinol-phosphatase, 3-isopropylmalate and threonine synthase as antibiotics | |
US20050026237A1 (en) | Methods for the identification of inhibitors of fumarate reductase as antibiotics | |
WO2005005602A2 (en) | Methods for the identification of inhibitors of fumarate reductase and vacuolar protein sorting-associated protein as antibiotics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003547565 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002803979 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2469772 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2002803979 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002803979 Country of ref document: EP |